Open AccessBictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus
Author(s) -
Nathanial S Nolan,
Samantha E. Adamson,
Dominic N. Reeds,
Jane A. O’Halloran
Publication year - 2021
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofab077
Subject(s) - medicine , antiretroviral therapy , adverse effect , diabetes mellitus , human immunodeficiency virus (hiv) , dolutegravir , diabetic ketoacidosis , integrase inhibitor , virology , intensive care medicine , viral load , endocrinology
Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is first line for treatment of people with human immunodeficiency virus (PWH). Emerging data suggest the possibility of adverse metabolic effects of these medications. We describe 3 cases in which PWH developed hyperglycemia and ketoacidosis within months of being switched to bictegravir-based ART.